Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report

BACKGROUND: Prostate cancer is a heterogeneous disease, meaning patients would benefit from different treatment strategies based on their molecular stratification. In recent years, several genomic studies have identified prostate cancers with defects in DNA repair genes. It is known that the PARP in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yi, He, Lijie, Huang, Qianwen, Zheng, Shuang, Zhang, Zhiqiang, Li, Hongshi, Liu, Shuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192270/
https://www.ncbi.nlm.nih.gov/pubmed/30333000
http://dx.doi.org/10.1186/s12881-018-0703-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192270/
https://www.ncbi.nlm.nih.gov/pubmed/30333000
http://dx.doi.org/10.1186/s12881-018-0703-9

Ejemplares similares